Sanofi-Synthélabo has decided to discontinue ANDROMEDA under advisementfrom its steering committee and the independent Data Safety and MonitoringBoard (DSMB) for the study, the company announced recently. ANDROMEDA wasa double-blind, placebo-controlled study in the process of evaluating theuse of dronedarone in high-risk patients with congestive heart failure andventricular dysfunction. A total of 627 of the intended 1,000 patients hadalready been enrolled in the study.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More